Drugs / ET1402L1-ARTEMIS™2 T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03888859 | Dec 2017 → Apr 2019 | hepatocellular carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET1402L1-ARTEMIS2 T cells | “Clinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ )...” NCT03888859 ↗ |
| Known as | ET1402L1-ARTEMIS T cells | “ET1402L1-ARTEMIS™ T cells -IV” NCT03888859 ↗ |
| Modality | Cell therapy | “Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm” NCT03888859 ↗ |
| Route | Other | “ET1402L1-ARTEMIS™2 T-cells administered through intravenous infusion” NCT03888859 ↗ |
| Target | AFP | “The molecular target for ET1402L1-ARTEMIS™2 is human leukocyte antigen (HLA) -A02 complexed with a HLA-A02-restricted peptide of alpha fetoprotein (AFP)” NCT03888859 ↗ |